346 Views

MRD’s Next Decade: Improving Accuracy and Precision of Tumor-Informed MRD to Standardizing Epigenetics and Fragmentomics for Tumor Agnostic MRD

Wednesday, November 12, 2025

9:00 AM - 9:50 AM EST

Location: 152, Level 1

Corporate Workshop Speaker(s)

AA

Andrew Anfora

LGC
RG

Russell Garlick

LGC
JG

Jim Godsey, PhD

Scientific Co-Chair Committee
BLOODPAC
Christina Lockwood, PhD

Professor of Laboratory Medicine and Pathology
University of Washington Medical Center
Seattle, Washington, United States
Klaus Pantel

Institute Director
UKE Hamburg Germany, Germany
VP

Varun Pattani

Vice President
Foundation Medicine

Molecular Residual Disease (MRD) surveillance continues to improve the lives of patients by providing actionable feedback weeks to months faster than that of legacy biomarkers such as imaging tests. This session is a roundtable discussion about the best practices in analytic validation of MRD assays with members of the scientific community representing assay developers, clinical testing laboratories, and reference standard providers focusing on best practices and concerns for analytic validation of tumor-informed assays and tumor agnostic assays.